[Translation] A Phase III, multicenter, randomized, double-blind, sham-controlled study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of intravitreal RO7200220 in patients with uveitic macular edema

在葡萄膜炎性黄斑水肿患者中评估新型重组、人源化抗白介素-6（IL-6）单克隆抗体 RO7200220的有效性、安全性、药代动力学和药效学

[Translation]

To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of a novel recombinant, humanized anti-interleukin-6 (IL-6) monoclonal antibody, RO7200220, in patients with uveitic macular edema

Start Date24 Oct 2024

Sponsor / Collaborator

F. Hoffmann-La Roche Ltd.

[+2]

CTRI/2024/02/062287

/ Not yet recruitingPhase 3

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Investigate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of RO7200220 Administered Intravitreally In Patients With Uveitic Macular Edema

Start Date15 Mar 2024

Sponsor / Collaborator

Roche Products (India) Pvt Ltd.

CTR20232119

/ Active, not recruitingPhase 3

一项在葡萄膜炎性黄斑水肿患者中评价 RO7200220 玻璃体内给药的有效性、安全性、药代动力学和药效学的III 期、多中心、随机、双盲、假治疗对照研究

在葡萄膜炎性黄斑水肿患者中评估新型重组、人源化抗白介素-6（IL-6）单克隆抗体 RO7200220的有效性、安全性、药代动力学和药效学

[Translation]

Start Date29 Aug 2023

Sponsor / Collaborator

F. Hoffmann-La Roche Ltd.

[+2]

100 Clinical Results associated with RO-7200220

100 Translational Medicine associated with RO-7200220

100 Patents (Medical) associated with RO-7200220

News (Medical) associated with RO-7200220

30 Jan 2025

·www.fiercepharma.com

Vabysmo crosses $4B mark, Polivy joins blockbuster club as Roche preps for key readouts

Roche CEO Thomas Schinecker highlighted 12 key pivotal trial readouts, including from four new molecular entities, that could happen in 2025. After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. Still, questions continue to swirl about an evolving market showdown with Regeneron’s rival drug.Vabysmo has supplanted cancer immunotherapy Tecentriq to take the No. 3 spot on Roche’s annual sales ranking. The bispecific eye injection brought in 3.86 billion Swiss francs ($4.3 billion), including 1.05 billion Swiss francs in the fourth quarter.Despite 43% year-over-year growth, Vabysmo’s fourth-quarter sales missed analyst expectations by 2%, according to Intron Health. The performance came after several quarters of Street-beating sales for the drug.During an investor call Thursday, Roche’s pharma chief Teresa Graham suggested that the fourth-quarter haul was affected by a “spend-down” and “significant channel filling” right after the launch of a more convenient prefilled syringe version of Vabysmo, which was approved by the FDA in July and EU in December.Starting in January, Roche is seeing “a strong trajectory” for Vabysmo sales, Graham said, assuring investors of continued strong growth and further market-share expansion in 2025.Vabysmo’s market share in the U.S. in the fourth quarter was 31% in neovascular age-related macular degeneration, 22% in diabetic macular edema and 23% in retinal vein occlusion. The numbers were 30%, 22% and 20%, respectively, in the third quarter.Graham stressed that Vabysmo’s fourth-quarter share numbers were not directly comparable to previous quarters because a data aggregator recently issued a “restatement” of third-quarter share figures. If analyzed by prior metrics, Vabysmo expanded by roughly three percentage points across each of the three indications, she said.Lately, the competition between Vabysmo and a high-dose version of Regeneron’s Eylea has been the focus of industry watchers. In September, European regulators also approved a prefilled syringe of Eylea HD. Nevertheless, Roche is “really not seeing any impact in any part of the world” from the arrival of Eylea HD, Graham said.The Roche exec highlighted how the two products’ syringes are “materially different,” as the Vabysmo product offers one-hand administration, she said. “When you think about it, if you’re doing […] 100 shots a day, having that real ease of administration is super important,” she added. “I would say we definitely have device preference going on our side.” As for Tecentriq, sales of the PD-L1 inhibitor declined by 3.3%—or remained flat at constant exchange rates—last year.“We do believe, as we have mentioned previously, that Tecentriq is getting close to peak, and we expect sales growth to be in the zero to low-single-digit range going forward,” Graham said.In 2024, Roche welcomed antibody-drug conjugate Polivy to the blockbuster club. With full-year sales of 1.12 billion Swiss francs, the drug ranked 16th on the company’s list of top meds.Although Polivy’s fourth-quarter sales, at 304 million Swiss francs, were flat over the prior quarter and came in 6% below Wall Street’s estimates, the drug expanded its U.S. market share in the key first-line diffuse large B-cell lymphoma indication to 29%, according to Graham.Roche has increasingly been leaning on new drugs like Vabysmo for growth. In 2024, a “young portfolio” of drugs contributed to 56% of Roche’s 46.2 billion Swiss francs of pharma sales, up from 51% in 2023. On Thursday’s call, Roche CEO Thomas Schinecker highlighted 12 key pivotal trial readouts, including from four new molecular entities, that could happen in 2025.One of the key assets is giredestrant. The oral SERD is nearing phase 3 readouts from the persevERA and evERA trials in HR-positive, HER2-negative breast cancer, around the middle or the second half of 2025, according to Roche. Schinecker has put the drug’s peak sales potential across multiple indications at above $3 billion.The other three new meds with pivotal readouts expected in 2025 are astegolimab in COPD, fenebrutinib in multiple sclerosis and vamikibart in uveitic macular edema.

Drug ApprovalPhase 3ADCBiosimilar

13 Apr 2023

·www.globenewswire.com

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

Vabysmo data suggest rapid and robust drying of retinal fluid in patients with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema Real-world studies of Vabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment in uveitic macular edema will be presented for the first time Basel, 13 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held from 23-27 April 2023 in New Orleans, United States. The abstracts showcase the strength and breadth of Roche’s Ophthalmology portfolio, including post-hoc data from phase III Vabysmo® (faricimab) studies that support its benefit in drying retinal fluid in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).1-3 Real-world data on Vabysmo treatment patterns and outcomes will be presented, as well as approaches to personalised healthcare that include the use of artificial intelligence (AI) modelling to predict retinal disease progression.4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME.8 “The breadth of data we are presenting at ARVO demonstrates our sustained commitment to preserving vision for people with potentially blinding retinal conditions,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “We are particularly encouraged by data indicating that Vabysmo may stabilise blood vessels and reduce fluid in the retina. Fluid control is essential for optimal central vision used for everyday activities such as reading and driving.” The following data will be presented at ARVO 2023: Vabysmo improves drying for people with nAMD and DME1-3A post-hoc analysis from the head-to-head dosing period of the phase III TENAYA and LUCERNE studies suggests Vabysmo results in greater drying of retinal fluid compared to aflibercept in people with nAMD. The data include change in central subfield thickness (CST), absence of subretinal and intraretinal fluid (SRF and IRF) and time to absence of SRF and IRF. A post-hoc analysis from the head-to-head dosing period of the phase III YOSEMITE and RHINE studies also supports the positive impact of Vabysmo on macular blood vessel leakage compared to aflibercept in people with DME. Outcomes include macular leakage area and the proportion of patients with minimal to no macular leakage - two important markers of vascular stability. Another analysis from YOSEMITE and RHINE suggests Vabysmo reduces retinal fluid when compared to aflibercept in people with DME. The data include time to absence of DME (CST <325 µm) and time to absence of IRF. Vabysmo extends dosing intervals early in the real world4,5Two Vabysmo real-world studies in nAMD and DME show patients extended their dosing intervals early in their treatment while maintaining or improving their vision. The majority of patients were able to extend their treatment intervals during the four initial doses. Treatment intervals were categorised as ‘extended’ if any interval was more than six weeks apart. Investigational IL-6 monoclonal antibody may benefit people with UME8Phase I data on an IL-6 inhibitor that is in development for UME and other retinal conditions suggest that this investigational monoclonal antibody improves visual acuity and CST in patients with UME. The IL-6 pathway plays an important role in the development and progression of UME by promoting blood vessel leakage and inflammation.9 UME is a complication of uveitis, a form of eye inflammation.10 This results in accumulation of fluid in the macula and can lead to significant visual impairment and vision loss.10 The estimated prevalence of uveitis is between 6 to 12 people per 10,000 globally, and approximately one-third of these people are impacted by UME.11 Roche recently launched two phase III trials in UME based on encouraging phase I safety and efficacy data. The first patients have been treated in the Meerkat (NCT05642312) and Sandcat (NCT05642325) studies, which are evaluating the safety and efficacy of the monoclonal antibody in people with UME.12,13 Roche is also studying the IL-6 inhibitor in DME.14 AI and machine learning6,7,15-17Roche will also present research related to the diagnosis and treatment of retinal conditions. These presentations include new research on the use of AI and machine learning to predict disease progression in geographic atrophy, a progressive and irreversible form of AMD; enable timely and accurate assessment of disease activity in nAMD or DME; predict treatment response in DME; and investigate new imaging biomarkers in diabetic retinopathy. Further information on select Roche abstracts that will be presented at ARVO 2023 can be found in the table below. TopicAbstract TitlePresentation Number /Presentation DetailsVabysmo Faricimab rapidly improves fluid outcomes in patients with neovascular age-related macular degenerationPoster Number: C0138Session: 123April 24 3:15 PM to 5:15 PM CDTEfficacy, durability, and safety of faricimab in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trialPoster Number: B0522Session: 148 April 25 8:45 AM to 10:30 AM CDTFaricimab causes rapid and sustained intraocular suppression of Ang-2 and VEGF-A for up to 16 weeks in neovascular age-related macular degeneration and diabetic macular edemaPoster Number: B0455 Session: 146 April 25 8:45 AM to 10:30 AM CDTDurable vision gains and greater fluid control with extended faricimab dosing versus aflibercept in patients with diabetic macular edema#2815 oral presentationSession: 153April 25 12:45 PM to 1:00 PM CDTFaricimab reduces macular leakage vs aflibercept in patients with DME #2816 oral presentationSession: 153April 25 1:00 PM to 1:15 PM CDTFaster time to retinal fluid control with faricimab in patients with DME in the phase 3 YOSEMITE/RHINE trials #2817 oral presentationSession: 153April 25 1:15 PM to 1:30 PM CDTIndividualized faricimab dosing up to every 16 weeks maintains robust anatomic and vision outcomes through 2 years in nAMD#5056 oral presentationSession: 271April 27 10:45 AM to 11:00 AM CDTUveitic Macular Edema A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study #5100 oral presentationSession: 277April 27 11:30 AM to 11:45 AM CDTA novel anti-IL-6 monoclonal antibody leads to restoration of IL-6-mediated endothelial barrier breakdown Poster Number: B0163Session: 284April 27 10:30 AM to 12:15 PM CDTReal-World Evidence FARETINA-AMD: Patient characteristics and initial clinical response of patients with neovascular age-related macular degeneration treated with faricimab in the IRIS RegistryPoster Number: C0171 Session: 124 April 24 3:15 PM to 5:00 PM CDTFARETINA-DME: Patient characteristics and initial clinical response of patients with diabetic macular edema treated with faricimab in the IRIS RegistryPoster Number: B0521 Session: 148 April 25 8:45 AM to 10:30 AM CDTSusvimoPort delivery system with ranibizumab in the treatment of diabetic retinopathy without center-involved diabetic macular edema: primary analysis results of the Phase 3 Pavilion trial#3754 oral presentationSession: 205April 26 11:00 AM to 11:15 AM CDTAI/Personalised Healthcare A pilot study of machine learning models for prediction of treatment response in patients with diabetic macular edema in a phase II clinical trialPoster Number: C0218Session: 21April 23 8:00 AM to 9:45 AM CDTDeep learning to predict future region of growth of geographic atrophy from fundus autofluorescence imagesPoster Number: C0211Session: 67April 23 3:45 PM to 5:30 PM CDTPredicting geographic atrophy growth rate with clinical and derived imaging featuresPoster Number: C0212Session: 67April 23 3:45 PM to 5:30 PM CDTOptical coherence tomography segmentation of retinal fluids using deep learningPoster Number: C0218Session: 67April 23 3:45 PM to 5:30 PM CDTDeep learning segmentation of foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) of nonproliferative diabetic retinopathyPoster Number: C0219Session: 67April 23 3:45 PM to 5:30 PM CDT About neovascular age-related macular degeneration Age-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading.18 Neovascular or ‘wet’ AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.19,20 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.19 Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.18,21,22 About diabetic macular edema Affecting around 21 million people globally, diabetic macular edema (DME) is a vision-threatening retinal condition associated with blindness and decreased quality of life when left untreated.23 DME occurs when damaged blood vessels leak into and cause swelling in the macula – the central area of the retina responsible for the sharp vision needed for reading and driving.24,25 The number of people with DME is expected to grow as the prevalence of diabetes increases.26 About the Vabysmo® (faricimab) clinical development programmeRoche has a robust phase III clinical development programme for Vabysmo. The programme includes AVONELLE-X, an extension study of TENAYA and LUCERNE evaluating the long-term safety and tolerability of Vabysmo in neovascular or ‘wet’ age-related macular degeneration (nAMD), and Rhone-X, an extension study of YOSEMITE and RHINE evaluating the long-term safety and tolerability of Vabysmo in diabetic macular edema (DME).27,28 In addition, Roche is investigating the efficacy and safety of Vabysmo in people with macular edema following retinal vein occlusion in two phase III studies, BALATON and COMINO.29,30 Roche has also initiated several phase IV studies, including the Elevatum study of Vabysmo in underrepresented patient populations with DME, the SALWEEN study of Vabysmo in a subpopulation of nAMD highly prevalent in Asia, as well as the VOYAGER study, a global real-world data collection platform.31-33 Roche also supports several other independent studies to further understand retinal conditions with a high unmet need.14 About Vabysmo® (faricimab)Vabysmo is the first bispecific antibody approved for the eye.34,35 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).36,37 Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation.36,37 By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels. Vabysmo is approved in 60 countries around the world, including the United States (U.S.), Japan, the United Kingdom and in the European Union for people living with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema.14,34,35,38,39 Review by other regulatory authorities is ongoing. About Roche in ophthalmologyRoche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients. We have the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye diseases. Our pipeline includes gene therapies and treatments for geographic atrophy and other vision-threatening diseases, including rare and inherited conditions. Applying our extensive experience, we have already brought breakthrough ophthalmic treatments to people living with vision loss. Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is the first U.S. Food and Drug Administration-approved refillable eye implant for neovascular or ‘wet’ age-related macular degeneration that continuously delivers a customised formulation of ranibizumab over a period of months.40 Vabysmo® (faricimab) is the first bispecific antibody approved for the eye, which targets two signalling pathways that drive retinal conditions.34,37 Lucentis®* (ranibizumab injection) is the first treatment approved to improve vision in people with certain retinal conditions.41 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.References[1] Querques G, et al. Faricimab rapidly improves fluid parameters in patients with neovascular age-related macular edema (nAMD). Poster at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2023 April 23-27 Abstract #2185.[2] Goldberg RA, et al. Faricimab reduces macular leakage versus aflibercept in patients with diabetic macular edema (DME). Presentation at: ARVO Annual Meeting; 2023 April 23-27 Presentation #2816.[3] Pollreisz A, et al. Faster time to retinal fluid control with faricimab versus aflibercept in patients with DME in the phase III YOSEMITE/RHINE trials. Presentation at: ARVO Annual Meeting; 2023 April 23-27 Presentation #2817.[4] Borkar DS, et al. FARETINA-AMD: Patient characteristics and initial clinical response of patients with nAMD treated with faricimab in the Intelligent Research in Sight (IRIS) Registry. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #2218. [5] Tabano D, et al. FARETINA-DME Patient characteristics and initial clinical response of patients with DME treated with faricimab in the IRIS Registry. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #2699. [6] Anegondi N, et al. Deep learning to predict future region of growth of geographic atrophy (GA) from fundus autofluorescence images. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #1117.[7] Cluceru J, et al. Predicting GA growth rate with clinical and derived imaging features. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #1118.[8] Sharma S, et al. A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase I DOVETAIL study. Presentation at: ARVO Annual Meeting; 2023 April 23-27 Presentation #5100.[9] Mesquida M, et al. Modelling macular edema: The effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro. Transl Vis Sci Technol. 2019;8(5):32.[10] Sood G, Patel BC. UME. [Internet; updated Aug 2022; cited April 2023]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562158/. [11] Roche data on file[12] Clinical Trials.gov. A Study to Investigate RO7200220 in Participants With Uveitic Macular Edema (Meerkat) [Internet; cited April 2023]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05642312. [13] Clinical Trials.gov. RO7200220 in Participants With Uveitic Macular Edema (Sandcat) [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05642325. [14] Roche data on file.[15] Lu H, et al. Optical coherence tomography segmentation of retinal fluids using deep learning. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #1124.[16] Wen Z, et al. A pilot study of machine learning models for prediction of treatment response in patients with DME in a phase II clinical trial. Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #241.[17] Camino Benech A, et al. Deep learning segmentation of foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) of non-proliferative diabetic retinopathy (DR). Poster at: ARVO Annual Meeting; 2023 April 23-27 Abstract #1125.[18] Bright Focus Foundation. AMD: facts and figures. [Internet; cited April 2023]. Available from: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. [19] Pennington KL, DeAngelis MM. Epidemiology of AMD: associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision. 2016;3:34.[20] Little K, et al. Myofibroblasts in macular fibrosis secondary to nAMD - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-91.[21] Connolly E, et al. Prevalence of AMD-associated genetic risk factors and four-year progression data in the Irish population. Br J Ophthalmol. 2018;102:1691–5.[22] Wong WL, et al. Global prevalence of AMD and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:106–16.[23] Yau JWY, et al. Global prevalence and major risk factors of DR. Diabetes Care. 2012;35:556–64.[24] National Eye Institute. DR. [Internet; cited April 2023]. Available from: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy. [25] All About Vision. Macula lutea. [Internet; cited April 2023]. Available from: https://www.allaboutvision.com/resources/macula. [26] Liu E, et al. DME: clinical risk factors and emerging genetic influences. Clin Exp Optom. 2017;100:569–76.[27] Clinical Trials.gov. A study to evaluate the long-term safety and tolerability of Vabysmo in participants with nAMD (AVONELLE-X) [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04777201. [28] Clinical Trials.gov. A study to evaluate the long-term safety and tolerability of Vabysmo in participants with DME (Rhone-X) [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04432831.[29] Clinical Trials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to branch retinal vein occlusion (BALATON) [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04740905.[30] Clinical Trials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to central retinal or hemiretinal vein occlusion (COMINO) [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04740931. [31] Clinical Trials.gov. A study to investigate faricimab treatment response in treatment-naïve, underrepresented patients with DME (ELEVATUM). [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05224102. [32] APVRS. Design and Rationale of the SALWEEN Trial: A phase IIIb/IIII study of faricimab, a dual angiopoietin-2 and vascular endothelial growth factor-A inhibitor, in patients with polypoidal choroidal vasculopathy. [Internet; cited April 2023]. Available from: https://2022.apvrs.org/abstract/?code=200351. [33] Clinical Trials.gov. A real-world study to gain clinical insights into Roche ophthalmology products (VOYAGER). [Internet; cited April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05476926. [34] United States Food and Drug Administration (U.S. FDA). Highlights of prescribing information, Vabysmo. 2022 [Internet; cited April 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf. [35] Medicines and Healthcare products Regulatory Agency. MHRA approves faricimab through international work-sharing initiative [Internet; cited April 2023]. Available from: https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative. [36] Heier JS, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for nAMD (TENAYA and LUCERNE): two randomised, double-masked, phase III, non-inferiority trials. The Lancet. 2022; 399:729-740.[37] Wykoff C, et al. Efficacy, durability and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with DME (YOSEMITE and RHINE): two randomised, double-masked, phase III trials. The Lancet. 2022; 399:741-755.[38] Chugai Pharmaceutical Co. Ltd. Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for nAMD and DME [Internet; cited April 2023]. Available from: https://www.chugaipharm.co.jp/english/news/detail/20220328160002_909.html. [39] European Medicines Agency. Summary of Product Characteristics, Vabysmo, 2022 [Internet; cited April 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-productinformation_en.pdf. [40] U.S. FDA. Highlights of prescribing information, Susvimo. 2006 [Internet; cited April 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf. [41] U.S. FDA. Highlights of prescribing information, Lucentis. 2006 [Internet; cited April 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 79 407 72 58Nathalie AltermattPhone: +41 79 771 05 25Karsten KleinePhone: +41 79 461 86 83Nina MählitzPhone: +41 79 327 54 74 Dr. Barbara von SchnurbeinPhone: +41 79 699 97 44Sileia Urech Phone: +41 79 935 81 48 Roche Investor Relations Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr. Sabine BorngräberPhone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.comDr. Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.comDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com Investor Relations North America Loren KalmPhone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment 13042023_MR_ARVOannual_meeting_en

Phase 3Phase 1Drug ApprovalClinical ResultPhase 2

100 Deals associated with RO-7200220

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uveitic Macular Edema	Phase 3	United States	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	China	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Austria	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Brazil	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Canada	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Israel	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Italy	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Mexico	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Netherlands	F. Hoffmann-La Roche Ltd.	09 Jan 2023
Uveitic Macular Edema	Phase 3	Poland	F. Hoffmann-La Roche Ltd.	09 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2023	Not Applicable	Uveitic Macular Edema	-	RG6179 0.25 mg	pwvresjire(ckctjwjieg) = Ocular AEs (n=27) were reported in the study eye of 16 of 33 patients. Of those AEs; 21 were mild, 5 were moderate, 1 was severe (worsening of uveitis; unrelated). Only 1 AE in 1 patients was reported as related to RG6179 (transient visual acuity loss). Two patients had progression of pre-existing cataract; none developed new cataracts. There were no cases of treatment-related intraocular pressure increase, occlusive retinal vasculitis or systemic AEs. paqifihfga (qfnsbfbwkn )	-	05 Oct 2023
				RG6179 1 mg
DOVETAIL (ARVO 12023 \| ARVO 22023) Manual	Phase 1	Uveitic Macular Edema	33	RG6179 0.25 mg	bubpptpkea(hxcvdsnlgk) = xrsldxvcpu qrjeojlcyu (euhuvbjzri ) View more	Positive	01 Jun 2023
				RG6179 1 mg	bubpptpkea(hxcvdsnlgk) = frcknultgg qrjeojlcyu (euhuvbjzri ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis